King Needs Second Trial In Order To Get Pediatric Extension for Altace
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has until October 2008 to complete another study after initial FDA rejection.
You may also be interested in...
Altace Follow-On Could Clear FDA By Year-End
New formulation from Arrow would allow King to extend the life of its ramipril brand.
King Signs Generic Altace Distribution Agreement With Cobalt
Patent infringement litigation between the two companies is ongoing.
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.